Inhibition of Toll-Like Receptor-Mediated Inflammation *in vitro* and *in vivo* by a Novel Benzoxaborole

Chen Dong, Holly Sexton, Ana Gertrudes, Tsutomu Akama, Shamra Martin, Charlotte Virtucio, Chiao-Wen Chen, Xiaoqin Fan, Anne Wu, Wei Bu, Liang Liu, Lisa Feng, Kurt Jarnagin, Yvonne R Freund

Anacor Pharmaceuticals, Inc. Palo Alto, CA 94303, USA

Running title: AN3485 inhibits TLR-mediated inflammation *in vitro* and *in vivo*

Corresponding author: Chen Dong

Anacor Pharmaceuticals

1020 E Meadow Circle

Palo Alto, CA 94303

Phone: 650-543-7535

Fax: 650-543-7660

Email: cdong@anacor.com

Total text pages: 38

Tables: 2

Figures: 8

References: 53

Words in the Abstract: 161

Words in Introduction: 656

Words in Discussion: 852

Abbreviations: AN3485, 6-(4-(aminomethyl)-2-chlorophenoxyl)benzo[c][1,2]oxaborol-1(3H)-ol;

TLR, Toll-like receptor; TIR, toll-interleukin 1 receptor; LPS, lipopolysaccharide; TNF-α, tumor

necrosis factor; IL, interleukin; GAPDH, glyceraldehydes-3-phosphate dehydrogenase; MTS, (3-

(4,5-dimethylthiazol-2-yl)-5-(3-carboxylmethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium);

IC_{50}, 50% inhibitory concentration; ED_{90}, 90% inhibitory dose; PEG400, polyethylene glycol-

400; PG, propylene glycol; FACS, fluorescence-activated cell sorting; PK, pharmacokinetics;

PAMP, pathogen-associated molecular pattern; DAMP, damage-associated molecular pattern.

Recommended section: Inflammation, Immunopharmacology, and Asthma

Abstract

Pro-inflammatory cytokines play a critical role in the development of autoimmune and inflammatory diseases. Targeting the cytokine environment has proven efficient for averting inflammation. In this study, we reported that 6-(4-(aminomethyl)-2-chlorophenoxyl)benzo[c][1,2]oxaborol-1(3H)-ol (AN3485), a benzoxaborole analog, inhibited TLR2-, TLR3-, TLR4- and TLR5-mediated TNF-α, IL-1β and IL-6 release from human PBMCs and isolated monocytes with IC_{50}s ranging from 18 to 580 nM, and the inhibition was mediated at the transcriptional level. Topical administration of AN3485 significantly reduced PMA-induced contact dermatitis and oxazolone-induced delayed-type hypersensitivity in mice, indicating its capability of penetrating skin and potential topical application in skin inflammation. Oral administration of AN3485 showed dose-dependent suppression of LPS-induced TNF-α and IL-6 production in mice with an ED_{90} of 30 mg/kg. Oral AN3485, 35 mg/kg, twice a day, suppressed collagen-induced arthritis in mice over a 20-day period. The potent anti-inflammatory activity in *in vitro* and *in vivo* disease models makes AN3485 an attractive therapeutic lead for a variety of cutaneous and systemic inflammatory diseases.

Introduction

Pro-inflammatory cytokines such as TNF-α, IL-1β and IL-6 have proven to be good therapeutic targets for rheumatoid arthritis (RA), psoriatic arthritis and psoriasis (Kopf et al., 2010). Identification of the mechanism whereby these cytokines are induced will not only help to understand the pathogenesis of these diseases, but also provide a potential target for drug development. The association of aberrant Toll-like receptors (TLR) responses with these diseases (Huang and Pope, 2009; Miller, 2008; Lai and Gallo, 2008; Carrasco et al., 2011) and the fact that activation of certain TLRs induces TNF-α, IL-1β and IL-6 production allows speculation that TLR signaling may play a role in disease initiation and/or progression.

TLRs were initially identified as receptors for exogenous pathogen-associated molecular patterns (PAMPs) of microbial origin (Poltorak et al, 1998), and act as the first line of defense against bacterial or viral infection (Dinarello, 2009). In addition to PAMPs, TLRs also recognize endogenous damage-associated molecular pattern (DAMP) molecules, such as heat shock proteins, nucleic acids from necrotic cells, high mobility group protein 1 (HMGB1) and extracellular matrix molecules, and activation of TLRs by DAMPs results in production of inflammatory mediators and tissue repair gene synthesis, by which to participate in tissue damage response and repair (Marshak-Rothstein, 2006; Piccinini and Midwood, 2010). Activation of TLRs is tightly controlled to maintain homeostasis, however, in some pathogenic contexts, TLRs are over-activated to produce excessive amounts of inflammatory mediators such as TNF-α, IL-1β and IL-6, which subsequently contribute to the pathogenesis of inflammatory disorders. The association of TLR signaling with these diseases promotes sustained efforts to develop novel drugs to block these pathways for a variety of disease indications. Attempts have

been directed toward interfering with the association of TLRs with ligands or intracellular

adaptor molecules (Hennessy et al., 2010; Loiarro et al., 2010), inhibiting the activation of

critical kinases in TLR cascades (Lindstrom and Robinson, 2010; O'Neill, 2003), and blocking

the functions of inflammatory cytokines (Kopf et al., 2010). Antagonists of TLRs and specific

kinase inhibitors are either in pre-clinical development or at various stages of clinical trials

(Hennessy et al., 2010; Lindstrom and Robinson, 2010). Targeting cytokines, such as TNF-α,

IL-1β, IL-6 and IL-23 with biologics, has proven beneficial and applied in clinical practice for

different diseases (Kopf et al., 2010). However, a significant portion of patients have a

suboptimal response to the biologic therapies (Bousquet et al., 2008; Leonardi et al., 2003;

Cohen et al., 2002), and together with issues of cost, convenience and safety (Tak and Kalden,

2011; Shear, 2006), there is a continuing unmet medical need for an orally available small

molecule that able to inhibit the production of inflammatory cytokines.

A new class of boron-containing small molecules has been developed over the past several

years as potential drugs. Different from carbon, boron contains an electrophilic empty p-orbital

which can form transient bonds with nucleophiles in an enzyme active site, which mimics a

tetrahedral transition state of peptide bond cleavage in an enzymatic reaction (Baker et al., 2011).

The benzoxaboroles, in which the boron atom is incorporated into a heteroaromatic ring system,

are able to inhibit a number of important enzymes, including bacterial and fungi Leucyl-tRNA

synthetase (Rock et al., 2007), human phosphodiesterase-4 (PDE4) (Akama et al., 2009) and

HCV NS3/4A protease (Li et al., 2010). Three benzoxaboroles, AN2690 (Tavaborole), AN2728

and AN3365 (GSK'052) are in clinical trials for treatment of onychomycosis, psoriasis/atopic

dermatitis and Gram-negative bacterial infection, and have been proven safe in human when applied topically or systemically.

In this paper, we report that a novel benzoxaborole analog, AN3485, effectively inhibits LPS (TLR4)-induced cytokine synthesis *in vitro* and *in vivo*. It also suppresses Zymosan (TLR2)-, polyinosinic-polycytidylic acid (Poly I:C, TLR3)- and Flagellin (TLR5)-induced cytokine release from human PBMCs. *In vivo* anti-inflammatory activity of AN3485 in topical and systemic disease models is also demonstrated. These results indicate that this benzoxaborole analog may provide a new approach for treatment of autoimmune and inflammatory disorders.

Materials and Methods

Animals. CD-1 and BALB/c female mice were purchased from Charles River Laboratories (Hollister, CA), and DBA/1J male mice were purchased from Jackson Laboratories (Bar Harbor, ME). All animal studies were performed with the approval of IACUC committees in accordance with the Guide for the Care and Use of Laboratory Animals (National Academy Press, Washington, DC, 2011).

Materials. AN3485, 6-(4-(aminomethyl)-2-chlorophenoxyl)benzo[c][1,2]oxaborol-1(3H)-ol, was synthesized at Anacor Pharmaceuticals as described in patent application WO 2010028005 A1. All lots used had purity >95% as assessed by HPLC and ^{1}H-NMR. *E. coli* B2 LPS, polyinosinic-polycytidylic acid (Poly (I:C)) and Histopaque-1077 were purchased from Sigma (St Louis, MO). Zymosan and recombinant Flagellin were obtained from InvivoGen (San Diego, CA). Human TNF-α, IL-1β and IL-6 cytokine determination kits were from Cisbio (Bradford, MA). EasySep human monocyte enrichment kit and RosetteSep human T cell enrichment cocktail were bought from StemCell Technologies (Vancouver, Canada). RNeasy mini kit was from Qiagen (Valencia, CA). Dynabeads human T-activator CD3/CD28, human TNF-α, IL-1β, IL-6 and GAPDH TaqMan qPCR probes and primers were from Invitrogen (Carlsbad, CA). CellTiter 96 aqueous one solution cell proliferation assay (MTS) was obtained from Promega (Madison, WI). Rapid Equilibrium Dialysis (RED) device was bought from Thermo Scientific (Rockford, IL).

Cell isolation, culture and stimulation. Human buffy coats used in this study were from healthy donors randomly recruited by Stanford Blood Center (Palo Alto, CA) aging 17 or older.

8

PBMCs were isolated from pools of buffy coats, collected from 8 donors, by using Histopaque-1077, aliquoted and frozen in liquid nitrogen. To purify human primary monocytes, PBMCs isolated from an individual buffy coat were further enriched using EasySep human monocyte enrichment kit according to the manufacturer's instructions. Human T cells were isolated from single donor buffy coat using RosetteSep human T cell enrichment cocktail based on the instructions from the manufacturer.

Human PBMCs, monocytes and T cells were cultured in RPMI 1640 supplemented with 10% FBS, 2 mM glutamine and 10 mM HEPES (complete media), in a 95% air /5% CO_2 incubator. AN3485 was dissolved in 100% DMSO at 40 mM before further 10-fold serial dilution in cell culture media with final concentrations ranging from 0.1 nM -100 μM. Cells cultured with 0.25% of DMSO were used as the untreated control in the *in vitro* assays. 5×10^5 PBMCs were seeded in each well of a 96-well plate for 3 h, and pre-incubated with AN3485 for 15 min before stimulation with 1 μg/ml of LPS in a final volume of 200 μl. After 24 h, the cell culture supernatants were collected for cytokine determinations using Cisbio HTRF cytokine determination kits. The same procedures were used for the experiments stimulated with Zymosan (30 μg/ml), Poly I:C (10 μg/ml) and Flagellin (300 ng/ml). For the experiments using human monocytes, 1×10^5 freshly isolated monocytes were seeded in each well and cultured for 1.5 h before stimulation. To stimulate human T cells, 2×10^5 freshly purified T cells were seeded in each well for 1.5 h, and stimulated with Dynabeads human T-activator CD3/CD28 for 48 h.

RNA isolation and real time PCR. Freshly isolated monocytes from individual donor's buffy coat were cultured at 5×10^5 cells/ml for 1.5 h, and then treated with AN3485 for 15 min before stimulation with either LPS, Zymosan, Poly I:C or Flagellin for indicated time periods. Cell culture supernatants were collected for cytokine determinations. Total RNAs were isolated from cell pellets by using an RNeasy mini kit based on manufacturer's instructions. The mRNAs of TNF-α, IL-1β and IL-6 were quantitated by real time PCR using TaqMan probes and primers and normalized to the level of the endogenous control, GAPDH.

In vitro **kinase assay.** Kinase assays were performed in Reaction Biology (Malvern, PA) (Ma et al., 2008) with 30 μM of AN3485. For the assays with IRAK1/4, TAK1, TBK1, MAP3K8, MEK1/2, MKK4/6, p38α/β/δ/γ, MAPKAPK2/3/5, ERK1/2, IKKα/β/ϵ, AKT1/2/3, JNK1/2/3, PKCα/β1 and PKA, 1 μM of [γP^{33}]-ATP and appropriate substrates were used. For the assays with PI3Kα/β/γ/δ, 10 μM of [γP^{33}]-ATP was added in each reaction.

Cytotoxicity (MTS assay). Human PBMCs and monocytes pre-treated with AN3485 for 15 min were stimulated with LPS for 1 day. The cells were then suspended in 100 μl of fresh complete medium and incubated with 20 μl per well of MTS solution for 4 h to allow color development. The absorbance at 490 and 690 nm was recorded. Inhibition of cell viability was calculated based on the formula: % inhibition of cell viability = 100- (ΔOD$_{\text{AN3485 treated}}$ / ΔOD$_{\text{untreated}}$) x 100. ΔOD = OD$_{490}$-OD$_{690}$.

Pharmacokinetics (PK) study of AN3485. Thirty-six CD-1 female mice were divided into 3 groups with 12 mice/group, and received AN3485 either by intravenous injection (IV) with 5

mg/kg in a solution composed of 50% saline, 40% PEG400 and 10% DMSO (50/40/10

Saline/PEG400/DMSO, pH 5.7), or by gavage (PO) or subcutaneous injection (SC) with 10

mg/kg in 70/25/5 PEG400/PG/DMSO solution. Blood samples were collected in K_2EDTA-

coated tubes at 8 time points during a 24 h period with 3 mice each time point. Plasma

concentration of AN3485 was determined by LC/MS/MS, with Lower Limit of Quantitation

(LLOQ) $\geq$8 ng/ml. The mean plasma concentration-time profiles were analyzed using

WinNonlin Pro version 5.2 with a two compartmental model for the IV data and a non-

compartmental model for both PO and SC data.

LPS-induced cytokine production in mice. The general procedures were as described by

Gozzi et al. (1999) with some modifications. Female CD-1 mice (20-30 g), 10 mice per group,

were orally dosed with AN3485, dissolved in vehicle 70/25/5 PEG400/PG/DMSO solution, one

hour before intraperitoneal injection (IP) with 10 µg/kg of LPS in 0.9% saline. One hour post

LPS administration, the mice were euthanized, blood was collected in a K_2EDTA-coated tube by

cardiac puncture, and plasma was obtained for cytokine determination and PK analysis.

Topical PMA-induced irritant contact dermatitis. CD-1 female mice (20-30 g), 5

mice/group, were used in this study based on a protocol described by Kuchera et al. (1993) with

a few modifications. 5 µg of PMA (phorbol 12-myristate 13-acetate) in 20 µl of ethanol were

applied topically to the anterior and posterior surface of the right ear of each mouse. 20 µl of

vehicle (ethanol:acetone, 1:1, vol/vol), 0.3 mg of dexamethasone (in 20 µl), 0.1, 0.3 or 1 mg of

AN3485 (in 20 µl) were administered to the same areas 30 min before and 15 min after PMA

application. The thickness of right and left ears of each mouse was measured 6 h after PMA

11

stimulation. Ear edema was calculated by subtracting the thickness of the left ear from that of

the right ear. Ears were then snap-frozen in a mixture of dry ice and ethanol, and homogenized

using Bullet Blender Homogenizer (Next Advance Inc., Averill Park, NY). The protein

concentrations of ear homogenates were quantitated by Bradford method using Bio-Rad protein

assay (Bio-Rad, Hercules, CA). Cytokines in ear homogenates were determined using BD

Cytometric bead array (BD Biosciences, San Diego, CA), and normalized to protein

concentration.

Topical oxazolone-induced allergic contact dermatitis. BALB/c female mice (20-30 g), 5

mice/group, were sensitized with 100 µl of 1.5% oxazolone (4-ethoxymethylene-2-

phenyloxazol-5-one) in acetone to their shaved abdomen, and 7 days later were challenged with

20 µl of 1% oxazolone at the anterior and posterior surface of the right ears (Evans et al., 1971).

20 µl of vehicle (ethanol:acetone, 1:1, vol/vol), 0.3 mg of dexamethasone (in 20 µl), 0.1, 0.3 or 1

mg of AN3485 (in 20 µl) was painted on the same areas of the right ears 30 min before and 15

min after oxazolone challenge. Ear edema was measured 24 h after oxazolone challenge by

subtracting the thickness of the left ear from that of the right ear. Ears were then snap-frozen and

homogenized for cytokine determination as described above.

Toxicity study. Female CD-1 mice (20-30 g), 5 mice/group, were orally dosed once a day

with 100 or 300 mg/kg of AN3485 in vehicle composed of 70% PEG400, 25% PG and 5%

DMSO for 7 days. Body weights and clinical observations were recorded daily. Blood samples

were collected in K_2EDTA-coated tubes 24 h after the last dose by cardiac puncture for

hematologic analysis, and spleens were collected, weighed, splenocytes were further isolated as

described by Fantini et al. (2007), and stained with anti-CD3, anti-CD45R (B220) and anti-CD11b (BD Biosciences, San Diego, CA) for FACS analysis.

Collagen-induced arthritis. DBA/1J male mice (6-7 weeks old) were immunized by subcutaneous injection with 50 µl of 2 mg/ml of bovine type II collagen emulsified with Complete Freund's adjuvant at the base of the tail, and boosted on day 21 with 50 µl of 2 mg/ml of collagen emulsified with Incomplete Freund's adjuvant. Body weight, overall physical condition and development of arthritis were assessed 3 times weekly, and clinical severity of arthritis in each paw was quantified based on a scale of 0-4 as described (Alonzi et al., 1998), and a cumulative disease score ranging from 0-16 was assigned for each mouse. When the cumulative disease score of a mouse reached 3.2, mice were randomly assigned to different groups with 10 mice per group (mice with cumulative disease scores <2 or >6 were excluded). AN3485 (BID), prednisolone (QD) or vehicle (BID) (70/25/5 PEG400/PG/DMSO solution) was orally administrated, and signs of arthritis and body weight were monitored once every other day for 20 days after dosing regimen. On day 20, the limbs were removed and immediately preserved in 10% formalin buffer, decalcified in 5% formic acid for 2-3 days, embedded in paraffin, sectioned at 8 µm and stained with toluidine blue to highlight the joint cartilage. Histologic slides were scored for synovial inflammation, pannus, cartilage damage and bone resorption, with all parameters on a scale of 0-5, where 0 indicated normal and 5 indicated severe as described by Bendele et al. (2000).

Statistical analysis. The data were presented as the mean ± standard deviation of the mean (SD). Differences between groups were analyzed using two-tailed unpaired Student's t-test.

13

Significance was considered when $p < 0.05$.

Results

AN3485 inhibits LPS-induced cytokine secretion *in vitro*. AN3485, a benzoxaborole with a

boron atom incorporated into the 5-membered ring of a six-five bicyclic system, inhibited LPS-

induced TNF-α, IL-1β and IL-6 secretion from human PBMCs and isolated monocytes with

IC$_{50}$s ranging from 18 to103 nM after 24 h exposure (Table 1). The effect of AN3485 on LPS-

induced cytokines was time-independent, because the IC$_{50}$s did not change when human PBMCs

were stimulated for 4, 8, 12, 16, 20 and 24 h (supplemental Figure 1). In comparison to

AN3485, Roflumilast (Daxas, Daliresp), a PDE4 inhibitor, and SB203580 (4-(4-Fluorophenyl)-

2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-1H-imidazole), a p38 MAPK inhibitor, inhibited LPS-

induced TNF-α, but had no effect on IL-6 release (supplemental Table 1). The distinct pattern of

cytokine blockade suggests that AN3485 may target a molecule different from PDE4 and p38

MAPK.

To ensure that the inhibition of cytokine secretion by AN3485 was not simply due to a

cytotoxic effect on cells, the viability of LPS-stimulated PBMCs and monocytes was

investigated by using MTS assay. More than 70% of cells survived after 24 h exposure to 100

μM of AN3485, and this compound had no effect on cell viability when PBMCs were stimulated

for 4 h (Fig. 1), at which time AN3485 showed comparable IC$_{50}$s against LPS-induced TNF-α,

IL-1β and IL-6 (supplemental Figure 1). These results indicated that the inhibitory capability of

AN3485 was unlikely due to a cytotoxic effect, instead, it inhibited TLR4-mediated cytokine

synthesis or secretion.

AN3485 reduces LPS-induced cytokine transcription. LPS-induced cytokines are regulated at both transcriptional (Economou et al., 1989; Yao et al., 1997; Xu et al., 2001) and post-transcriptional (Han et al., 1990; Lai et al., 1999; MacKenzie et al., 2002) levels. To elucidate whether AN3485 modulates the mRNA levels of these cytokines, the mRNAs of TNF-α, IL-1β and IL-6 in LPS-stimulated monocytes were quantitated. AN3485 concentration-dependently reduced the amounts of TNF-α, IL-1β and IL-6 mRNA in response to LPS stimulation, and at 3 h after LPS stimulation, 0.1 μM of the compound decreased these three cytokine mRNAs by 68%, 63% and 88% respectively (Fig. 2A). Correspondingly, AN3485 significantly inhibited the secretion of TNF-α and IL-6 proteins in cell culture supernatant (Fig. 2B). Although IL-1β mRNA was induced as early as 1 h upon LPS stimulation, and was 5- and 21-fold more abundant than IL-6 and TNF-α mRNA at the 3 h time point, IL-1β was undetectable in the culture supernatant even after 3 h stimulation. The absence of secreted IL-1β was expected since the secretion of IL-1β requires a rate-limiting second step to cleave pro-IL-1β (Netea et al., 2009; Carta et al., 2011).

AN3485 reduces TLR2-, TLR3- and TLR5-mediated cytokine production. To understand whether AN3485 also functions in other TLR-mediated pathways, the effect of AN3485 on Zymosan (TLR2)-, Poly I:C (TLR3)- and Flagellin (TLR5)-induced cytokine release was evaluated. In comparison to the effect on LPS stimulation, AN3485 had similar potency against Poly I:C- and Zymosan-induced TNF-α, IL-1β and IL-6 synthesis in human PBMCs with IC$_{50}$s ranging from 28 to 580 nM (Table 2), and the IC$_{50}$s did not show differences with 4 and 24 h activation (data not shown). AN3485 also prevented Flagellin-induced TNF-α and IL-6 release from human PBMCs with IC$_{50}$s of 190 and 80 nM when cells were stimulated for 4 h.

AN3485 reduces TLR2-, TLR3- and TLR5-mediated cytokine transcription. Effects of AN3485 on the mRNA levels of TNF-α, IL-1β and IL-6 were also observed when human monocytes were stimulated with Zymosan, Poly I:C or Flagellin. Induction of TNF-α and IL-6 mRNA in response to Zymosan was relatively slower than that in response to LPS, Poly I:C and Flagellin, such that IL-6 mRNA was barely induced by Zymosan even by 3 h. Transcription of TNF-α in response to Flagellin was rapid, but its mRNA level fell off quickly (Fig. 3A). After 3 h stimulation, 1 μM of AN3485 decreased Zymosan- and Poly I:C-induced TNF-α mRNA by 85% and 76%, Zymosan-, Poly I:C- and Flagellin-induced IL-1β mRNA by 80%, 52% and 84%, and Poly I:C- and Flagellin-induced IL-6 mRNA by 97% and 97% (Fig. 3A). As a consequence, the effect on transcription was translated to the inhibition of TNF-α and IL-6 proteins released to the culture supernatant (Fig. 3B). Together, these results indicated that AN3485 was able to inhibit TLR2-, TLR3- and TLR5-mediated cytokine release by effects on the transcription of these cytokines.

AN3485 is inactive against kinases in TLR signaling pathways. The possibility that AN3485 might act as an inhibitor of a kinase in TLR pathways was addressed by *in vitro* kinase assay. The activities of 34 kinases involved in TLR signaling (Gaestel et al., 2009) were tested. 30 μM of AN3485 had no effect on the activities of IRAK1/4, TAK1, TBK1, MAP3K8, MEK1/2, MKK4/6, p38α/β/γ/δ, MAPKAPK2/3/5, ERK1/2, IKKα/β/ε, AKT1/2/3, PI3Kα/β/γ/δ, JNK1/2/3, PKCα/β1 and PKA. Therefore, AN3485 apparently does not act as a kinase inhibitor by which blocking TLR-mediated TNF-α, IL-1β and IL-6 production.

AN3485 shows activity against T cell receptor (TCR)-mediated cytokine secretion. The activity of AN3485 against TCR-mediated cytokine production was investigated. AN3485 prevented anti-CD3/CD28-induced IL-2, IFN-γ, TNF-α, IL-4 and IL-13 secretion from purified human T cells with IC_{50}s of 1.07, 2.37, 2.45, 1.94 and 12.3 μM respectively, indicating that this activity is less potent than that against TLR-mediated cytokine production in monocytes. With concentrations up to 100 μM, AN3485 did not show effect on the viability of resting and activated T cells after 48 h exposure. Additionally, with 3 day incubation, the IC_{50} of AN3485 on the viability of Jurkat (a human T-cell line) was >30 μM.

Pharmacokinetics of AN3485. The pharmacokinetic profile of AN3485 was assessed in CD-1 mice. The plasma clearance of the compound was 2210 ml/h/kg following IV injection at 5 mg/kg. $T_{1/2}$ and $AUC_{0\text{-inf}}$ with oral administration of 10 mg/kg were 2.8 h and 3.05 h*μg/ml respectively, with optimal oral bioavailability of 59%. The *in vitro* plasma protein binding for AN3485 was 76.2% in mice as determined by using Rapid Equilibrium Dialysis (RED) device and quantitated by LC/MS/MS. These data indicated that adequate trough concentration of AN3485 would be achieved by dosing twice a day for a long term efficacy study.

Oral administration of AN3485 suppresses cytokine elaboration in response to LPS *in vivo*. Preliminary studies showed that intraperitoneal injection of 10 μg/kg of LPS induced significant amounts of TNF-α and IL-6 in mouse plasma with peak at 1 h post administration, which was consistent with what reported previously (Ruggiero et al., 1993; Gozzi et al, 1999). Pre-treatment with AN3485 dose-dependently decreased LPS-induced plasma levels of TNF-α and IL-6 in mice, with ED_{50} and ED_{90} values of approximately 8 and 30 mg/kg (Fig. 4). The

18

plasma levels of AN3485 with 8 and 30 mg/kg dosages at 2 h after administration were approximately 0.7 and 2.3 μM, which corresponded to 167 [0.7 μM × (100%-76.2%) = 0.167 μM] and 547 nM [2.3 μM × (100%-76.2%) = 0.547 μM] of free compound in the plasma as calculated based on the protein binding of 76.2% for AN3485. The concentrations of free AN3485 in plasma correlated well with the *in vitro* IC_{50}s and IC_{90}s of LPS-induced TNF-α (IC_{50} = 103 nM; IC_{90} = 1000 nM) and IL-6 (IC_{50} = 72 nM; IC_{90} = 500 nM), suggesting that likely the same mechanism was effected *in vitro* and *in vivo*. The ability of oral AN3485 against LPS-induced cytokine production *in vivo* supports its potential application in inflammatory diseases associated with these cytokines.

In vivo **toxicity of AN3485.** The toxicity of AN3485 was evaluated in preparation for long term efficacy studies. CD-1 mice were orally dosed once a day for 7 consecutive days with 100 or 300 mg/kg of AN3485 or vehicle. Clinical signs, including ataxia, rough coat, ptosis and lethargy, and 13-18 % decrease in body weight gains between day 1 and 5 were observed in 300 mg/kg group. No clinical signs and decrease in body weight gains were noted in 100 mg/kg group (Fig. 5A). In comparison to vehicle treated group, mice with 100 mg/kg of AN3485 had decreases in total white blood cells, lymphocytes and platelets, and lower hemoglobin levels (HGB) and hematocrits (HCT) in blood (Fig. 5B). However, untreated mice also showed lower values for each of these as compared to vehicle-treated controls, and there were no statistic differences of these parameters between untreated mice and 100 mg/kg AN3485 treated group. Hence, the effects of AN3485 at 100 mg/kg were not clinically significant. FACS analysis demonstrated that the major immune cells in the spleen, including T cells (CD3$^+$), B cells (B220$^+$) and monocytes/macrophages (CD11b$^+$), were not significantly altered in mice treated

19

with 100 mg/kg of AN3485 as compared to untreated group, although there was a decrease of T cells and an increase of B cells in AN3485 treated mice when comparing to vehicle treated group (Fig. 5C). Spleen weights were not statistically different among these three groups of mice (Fig. 5C). In conclusion, oral administration of AN3485 for 7 consecutive days did not result in any signs of overt toxicity at dose of 100 mg/kg/day, which is considered to be the No Observable Adverse Effect Level (NOAEL).

Topical application of AN3485 reduces PMA-induced acute contact dermatitis in mice.
PMA treated mice show local increases in expression of IL-1β and IL-6 (DeVry et al., 2005) as well as in vascular permeability (Lee et al., 1994), and have been used as an experimental model of irritant contact dermatitis. Topical treatment with 0.3 mg of dexamethasone reduced mice ear swelling by 64% 6 h after PMA stimulation. Topical AN3485 showed comparable effects: 0.1, 0.3 and 1 mg of AN3485 reduced ear edema by 21%, 76% and 90% respectively (Fig. 6A). Significant amounts of IL-1β and IL-6 were detected in mouse ear homogenate 6 h after PMA challenge (Fig. 6B). Topical 0.1, 0.3 and 1 mg of AN3485 inhibited PMA-induced IL-6 by 65%, 94% and 96%, and IL-1β by 70%, 84% and 91%, whereas 0.3 mg of dexamethasone blocked IL-6 and IL-1β by 70% and 54% (Fig. 6B).

Topical AN3485 reduces oxazolone-induced delayed-type hypersensitivity in mice. The effect of AN3485 on oxazolone-induced delayed-type hypersensitivity, a model of allergic contact dermatitis, was investigated. Topical application of 0.1, 0.3 and 1 mg of AN3485 reduced ear swelling by 58%, 92% and 100% 24 h after oxazolone challenge, whereas 0.3 mg of dexamethasone suppressed ear edema by 98% (Fig. 7A). Challenge with oxazolone also induced

significant amounts of IL-1β, IL-6, TNF-α and IL-4 in mice ears (Fig. 7B), but no IL-2, IL-13

and IFN-γ were detectable. Topical treatment with 0.1, 0.3 and 1 mg of AN3485 inhibited

oxazolone-induced IL-1β by 16%, 43% and 75%, IL-6 by 16%, 62% and 83%, TNF-α by 2%,

26% and 49%, and IL-4 by 14%, 49% and 72% (Fig. 7B). Dexamethasone, 0.3 mg/ear,

suppressed oxazolone-induced IL-1β, IL-6, TNF-α and IL-4 by 96%, 96%, 64% and 84% (Fig.

7B). Taken together, the effect of AN3485 on PMA- and oxazolone-induced ear edema and

cytokine production in mice ears indicated that this compound could penetrate through skin to

block skin inflammation, and supports the topical application of AN3485 in cutaneous

inflammatory disorders such as psoriasis and atopic dermatitis.

AN3485 inhibits collagen-induced arthritis in mice. In order to examine the ability of

AN3485 to suppress profound chronic inflammation, we examined its effects in collagen-

induced arthritis (CIA), a murine model of rheumatoid arthritis (RA). In the CIA model and in

RA patients, the synovial membrane is infiltrated by immune cells including macrophages and T

cells, which produce inflammatory mediators leading to pain, inflammatory cell infiltration,

swelling, and cartilage and bone erosion (Stuart et al, 1988). Mice given 35 mg/kg of AN3485

twice a day showed a dramatically curtailed rate of disease progression: the cumulative disease

score of the vehicle-treated group soared 9.3 during the 20-day period, whereas the AN3485-

treated group only increased 3.4, a 63% inhibition of the disease development (Fig. 8A). The

amelioration of arthritis by AN3485 was also confirmed by histological evaluation of the joints

collected on day 20. Mice treated with AN3485 showed less severity of inflammation and bone

erosion in joints of the limbs (Fig. 8B), with 67%, 85%, 81% and 85% inhibition of synovial

inflammation, pannus formation, cartilage damage and bone resorption (Fig. 8C). The dosage of

AN3485 was well tolerated: mice with AN3485 treatment showed no adverse events and had

similar body weight gain to the vehicle-treated counterparts.

Discussion

Excessive cytokine production contributes to the pathogenesis of a number of inflammatory and autoimmune diseases. Biologics targeting TNF-α, IL-6, IL-1 and IL-23 have shown beneficial effects in rheumatoid arthritis, psoriasis and Crohn's disease (Kopf et al., 2010; Leonardi, et al., 2003; Cohen, et al., 2002). However, due to incomplete responses in some patients and side effects of current available drugs, there is an unmet medical need for new immunosuppressive drugs. An orally or topically bioavailable small molecule capable of suppressing multiple critical cytokines, such as AN3485 described herein, may be a good approach for autoimmune and inflammatory diseases.

We demonstrated in this paper that AN3485 inhibited TLR-mediated TNF-α, IL-1β and IL-6 secretion with submicromolar IC_{50}s, and the effect was transcriptionally-mediated, since 100 nM of AN3485 could inhibit LPS-induced up-regulation of the mRNA levels of these three cytokines by 68%, 63% and 88% respectively. AN3485 at pharmacologically-effective concentrations had mild effects on the viability of monocytes, suggesting cytotoxicity is unlikely the mechanism contributing to cytokine blockade.

Eleven TLRs, which recognize a wide range of exogenous PAMPs and endogenous DAMPs, have been identified in human. Upon engagement with their cognate ligands, TLRs either homo- or hetero-dimerize to promote intracellular TIR-TIR interaction and recruit adaptor molecules to the complex (Jin and Lee, 2008). TLR3 recruits TRIF to induce TRIF-dependent response, while the other TLRs can interact with MyD88 to trigger MyD88-dependent signaling. The formation of TLR complex triggers the autophosphorylation of IRAK4 which further leads to the

23

signal cascade mediated by a number of kinases, and eventually results in the transcription of inflammatory mediators (Kawai and Akira, 2010; Han and Ulevitch, 2005; Gaestel, et al., 2009). Crystal structures of the extracellular domains of TLR2/TLR1 (Jin et al., 2007), TLR4/MD-2 (Kim et al., 2007; Park et al., 2009), TLR3 (Liu et al., 2008) and TLR5 (Yoon et al., 2012) with their ligands reveal that although these receptors differ in ligand recognition, they all form a common tail-to-tail "m"-shaped dimer, suggesting the possible conservation of the "m"-like structure among all TLR complexes. In this study, we demonstrated that AN3485 not only inhibited TLR4-mediated TNF-α, IL-1β and IL-6 production, but also blocked TLR2-, TLR3-, and TLR5-mediated cytokine synthesis at both mRNA and protein levels. Given the differences in the ligands and adaptor molecules associated with these TLR complexes, it is unlikely that AN3485 acts by depleting a TLR ligand or interacting directly with an adaptor molecule in the complex. Instead, AN3485 may bind to the conserved "m"-like structure of the complexes or target a molecule shared by the TLR pathways that leads to the transcription of the cytokines.

A number of kinases are activated upon the binding of a TLR agonist, and act as essential signaling components among the TLR pathways (Gaestel et al., 2009). *In vitro* kinase assays indicated that AN3485 was inactive against 34 kinases involved in TLR pathways. Further work to decipher the effect of the compound on TLR-mediated signaling pathways in human monocytes is in progress, and the results will help to understand the mechanism of action of the molecule.

In addition to blockade of TLR-mediated cytokine production, AN3485 also had some effect on TCR-mediated IL-2, IFN-γ, TNF-α, IL-4 and IL-13 synthesis. The potency of AN3485

against anti-CD3/CD28-induced TNF-α secretion from human T cells was 32-fold less than that against LPS-induced TNF-α release from monocytes, suggesting stronger inhibition of TLR signaling by AN3485. Although the activity against TCR-mediated cytokine secretion was relatively impotent, it may still contribute to the *in vivo* efficacy of AN3485 in the models of collagen-induced arthritis and oxazolone-induced delayed-type hypersensitivity, in which pathogenesis involves T cell activation.

Toxicity study indicated that mice orally dosed with 100 mg/kg/day of AN3485 for 7 days did not show clinical signs, and had no significant changes in blood components and immune cell populations in spleens. Oral administration of 35 mg/kg of AN3485 twice a day for 20 days was tolerable and had no effect on mice body weight gain. These results coincide with *in vitro* effect on cell viability, suggesting minimal effect of AN3485 on cell survival.

AN3485 reduced the profound inflammation of collagen-induced arthritis, a model resembles human rheumatoid arthritis. AN3485 suppressed all elements of the joint damage including pannus formation, bone erosion, invasion of inflammatory cells and cartilage damage by 67-85%, and attenuated the severity of established arthritis by 63% on day 20. The efficacy is comparable to that of anti-TNF-α biologics infliximab (Remicade) and etanercept (Enbrel) (~70%) (Joosten et al., 1999; Zalevsky et al., 2007) and a JAK1/2 inhibitor INCB028050 (Baricitinib, ~ 60%) (Fridman et al., 2010) which demonstrated beneficial effects in patients with active rheumatoid arthritis. The potency of AN3485 in CIA model makes it promising for the application in rheumatoid arthritis.

In conclusion, AN3485, a novel benzoxaborole, inhibits TLR-mediated pro-inflammatory

cytokine synthesis in a transcription-dependent manner. Topical application of AN3485 reduced

PMA- and oxazolone-induced skin inflammation. Oral AN3485 alleviated the chronic

inflammation associated with collagen-induced arthritis in mice. The potent anti-inflammatory

activity of AN3485 *in vitro* and in disease models indicates its potential therapeutic application

in acute and chronic inflammatory diseases such as rheumatoid arthritis, psoriasis and atopic

dermatitis.

26

Authorship Contributions

Participated in research design: Dong, Jarnagin and Freund.

Conducted experiments: Dong, Sexton, Gertrudes, Martin, Virtucio, Chen, Fan and Feng.

Performed data analysis: Dong, Chen, Wu, Bu and Liu.

Provided AN3485: Akama.

Wrote manuscript: Dong, Jarnagin and Freund.

References

Akama T, Baker SJ, Zhang YK, Hernandez V, Zhou H, Sanders V, Freund Y, Kimura R, Maples KR and Plattner JJ (2009) Discovery and structure-activity study of a novel benzoxaborle anti-inflammation agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis. *Bioorg Med Chem Lett* **19:** 2129-2132.

Alonzi T, Fattori E, Lazzaro D, Costa P, Probert L, Kollias G, De Benedetti F, Poli V and Ciliberto G (1998) Interleukin 6 is required for the development of collagen-induced arthritis. *J Exp Med* **187:** 461-468.

Baker SJ, Tomsho JW and Benkovic SJ (2011) Boron-containing inhibitors of synthetase. *Chem Soc Rev* **40:** 4279-4285.

Bendele AM, Chlipala ES, Scherrer J, Frazier J, Sennello G, Rich WJ and Edwards CK 3rd (2000) Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis. *Arthritis Rheum* **43:** 2648-2659.

Bousquet J, Chiron R and Humbert M (2008) Biologics in asthma: difficulties and drawbacks. *Expert Opin Biol Ther* **8:** 1921-1928.

Carrasco S, Neves FS, Fonseca MH, Goncalves CR, Saad CG, Sampaio-Barros PD and Goldenstein-Schainberg C (2011) Toll-like receptor (TLR)2 is upregulated on peripheral blood

monocytes of patients with psoriatic arthritis: a role for a gram-positive inflammatory trigger? *Clin Exp Rheumatol* **29:**958-962.

Carta S, Tassi S, Pettinati I, Delfino L, Dinarello CA, Rubartelli A (2011) The rate of interleukin-1 beta secretion in different myeloid cells varies with the extent of redox response to Toll-like receptor triggering. *J Biol Chem* **286:** 27069-27080.

Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, Kremer J, Bear MB, Rich WJ and McCabe D (2002) Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. *Arthritis Rheum* **46:** 614-624.

De Vry CG, Valdez M, Lazarov M, Muh E, Buelow R, Fong T and Iyer S (2005) Topical application of a novel immunomodulatory peptide, RDP58, reduces skin inflammation in the phorbol ester-induced dermatitis model. *J Invest Dermatol* **125:** 473-481.

Dinarello CA (2009) Immunological and inflammatory functions of the interleukin-1 family. *Annu Rev Immunol* **27:** 519-550.

Economou JS, Rhoades K, Essner R, McBride WH, Gasson JC and Morton DL (1989) Genetic analysis of the human tumor necrosis factor alpha/cachectin promoter region in a macrophage cell line. *J Exp Med* **170:** 321-326.

Evans DP, Hossack M and Thomson DS (1971) Inhibition of contact sensitivity in the mouse by topical application of corticosteroids. *Br J Pharmac*ol **43:** 403-408.

Fantini MC, Dominitzki S, Rizzo A, Neutath MF and Becker C (2007) In vitro generation of CD4+CD25+ regulatory cells from murine naïve T cells. *Nat Protoc* **2:** 1789-1794.

Fridman JS, Scherle PA, Collins R, Burn TC, Li Y, Li J, Covington MB, Thomas B, Collier P, Favata MF, Wen X, Shi J, McGee R, Haley PJ, Shepard S, Rodgers JD, Yeleswaram S, Hollis G, Newton RC, Metcalf B, Friedman SM and Vaddi K (2010) Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. *J Immunol* **184:** 5298-5307.

Gaestel M, Kotlyarov A and Kracht M (2009) Targeting innate immunity protein kinase signaling in inflammation. *Nat Rev Drug Discov* **8:** 480-499.

Gozzi P, Pahlman I, Palmer L, Gronberg A and Persson S (1999) Pharmacokinetic-pharmacodynamic modeling of the immunomodulating agent susalimod and experimentally induced tumor necrosis factor-alpha levels in the mouse. *J Pharmacol Exp Ther* **291:** 199-203.

Han J, Brown T and Beutler B (1990) Endotoxin-responsive sequences control cachectin/tumor necrosis factor biosynthesis at the translational level. *J Exp Med* **171:** 465-475.

Han J and Ulevitch RJ (2005) Limiting inflammatory responses during activation of innate immunity. *Nat Immunol* **6:** 1198-1205.

Hennessy EJ, Parker AE and O'Neill LA (2010) Targeting Toll-like receptors: emerging therapeutics? *Nat Rev Drug Discov* **9:** 293-307.

Huang QQ and Pope RM (2009) The role of toll-like receptors in rheumatoid arthritis. *Curr Theumatol Rep* **11:** 357-364.

Jin MS, Kim SE, Heo JY, Lee ME, Kim HM, Palk SG, Lee H and Lee JO (2007) Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. *Cell* **130**: 1071-1082.

Jin MS and Lee JO (2008) Structures of the Toll-like receptor family and its ligand complex. *Immunity* **29:** 182-191.

Joosten LA, Helsen MM, Saxne T, van De Loo FA, Heinegard D and van Den Berg WB (1999) IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation. *J Immunol* **163:** 5049-5055.

Kawai T and Akira S (2010) The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. *Nat Immunol* **11:** 373-384.

Kim HM, Park BS, Kim JI, Kim SE, Lee J, Oh SC, Enkhbayar P, Matsushima N, Lee H, Yoo OJ and Lee JO (2007) Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. *Cell* **130:** 906-917.

Kopf M, Bachmann MF and Marsland BJ (2010) Averting inflammation by targeting the cytokine environment. *Nat Rev Drug Discov* **9:** 703-718.

Kuchera S, Barth H, Jacobson P, Metz A, Schaechtele C and Schier D (1993) Anti-inflammatory properties of the protein kinase C inhibitor, 3-[1-[3-(dimethylamino)propyl]-1H-indol-3-yl]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione monohydrochloride (GF109203X) in the PMA-mouse ear edema model. *Agents Actions* **39 Spec No:** C169-173.

Lai WS, Carballo E, Strum JR, Kennington EA, Phillips RS and Blackshear PJ (1999) Evidence that tristetraprolin binds to AU-rich elements and promotes the deadenylation and destabilization of tumor necrosis factor alpha mRNA. *Mol Cell Biol* **19:** 4311-4323.

Lai Y and Gallo RL (2008) Toll-like receptors in skin infections and inflammatory diseases. *Infect Disord Drug Targets* **8:**144-155.

Lee WY, Lockniskar MF and Fischer SM (1994) Interleikin-1 alpha mediates phorbol ester-induced inflammation and epidermal hyperplasia. *FASEB J* **8:** 1081-1087.

Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, Gottlieb AB, Etanercept Psoriasis Study Group (2003) Etanercept as monotherapy in patients with psoriasis. *N Engl J Med* **349:** 2014-2022.

Li X, Zhang YK, Liu Y, Ding CZ, Li Q, Zhou Y, Plattner JJ, Baker SJ, Qian X, Fan D, Liao L, Ni ZJ, White GV, Mordaunt JE, Lazarides LX, Slater MJ, Jarvest RL, Thommes P, Ellis M, Edge CM, Hubbard JA, Somers D, Rowland P, Nassau P, McDowell B, Skarzynski TJ, Kazmierski WM, Grimes RM, Wright LL, Smith GK, Zou W, Wright J and Pennicott LE (2010) Synthesis and evaluation of novel alpha-amino cyclic boronates as inhibitors of HCV NS3 protease. *Bioorg Med Chem Lett* **20:** 3550-3556.

Lindstrom T and Robinson W (2010) A multitude of kinases – which are the best targets in treating rheumatoid arthritis? *Rheum Dis Clin North Am* **36:** 367-382.

Liu L, Botos I, Wang Y, Leonard JN, Shiloach J, Segal DM and Davies DR (2008) Structural basis of toll-like receptor 3 signaling with double-stranded RNA. *Science* **320:** 379-381.

Loiarro M, Ruggiero V and Sette C (2010) Targeting TLR/IL-1R signalling in human diseases. *Mediators Inflamm* **2010:** 674363.

Ma H, Deacon S and Horiuchi K (2008) The challenge of selecting protein kinase assays for lead discovery optimization. *Expert Opin Drug Discov* **3:** 607-621.

MacKenzie S, Fernandez-Troy N and Espel E (2002) Post-transcriptional regulation of TNF-alpha during in vitro differentiation of human monocytes/macrophages in primary culture. *J Leukoc Biol* **71:** 1026-1032.

Marshak-Rothstein A (2006) Toll-like receptors in systemic autoimmune disease. *Nat Rev Immuno* **6:** 823-835.

Miller LS (2008) Toll-like receptors in skin. *Adv Dermatol* **24:** 71-87.

Netea MG, Nold-Petry CA, Nold MF, Joosten LA, Opitz B, van der Meer JH, van de Veerdonk FL, Ferwerda G, Heinhuis B, Devesa I, Funk CJ, Mason RJ, Kullberg BJ, Rubartelli A, van der Meer JW and Dinarello CA (2009) Differential requirement for the activation of the inflammasome for processing and release of IL-1 beta in monocytes and macrophages. *Blood* **113:** 2324-2335.

O'Neill LA (2003) Therapeutic targeting of Toll-like receptors for inflammatory and infectious diseases. *Curr Opin Pharmacol* **3:** 396-403.

Park BS, Song DH, Kim HM, Choi BS, Lee H and Lee JO (2009) The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. *Nature* **458:** 1191-1195.

Piccinini AM and Midwood KS (2010) DAMPening inflammation by modulating TLR signaling. *Mediators Inflammm* **2010:** 1-21.

Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, Birdwell D, Alejos E, Silva M, Galanos C, Freudenberg M, Ricciardi-Castagnoli P, Layton B and Beutler B (1998) Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. *Science* **282:** 2085-2088.

Rock FL, Mao W, Yaremchuk A, Tukalo M, Crepin T, Zhou H, Zhang YK, Hernardez V, Akama T, Baker SJ, Plattner JJ, Shapiro L, Martinis SA, Benkovic SJ, Cusack S and Alley MRK (2007) An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site. *Science* **316:** 1759-1761.

Ruggiero V, D'Urso CM, Albertoni C, Campo S, Foresta P and Martelli EA (1993) LPS-induced serum TNF production and lethality in mice: effect of L-carnitine and some acyl-derivatives. *Mediators Inflamm* **2:** S43-50.

Shear NH (2006) Fulfilling an unmet need in psoriasis: do biologicals hold the key to improved tolerability? *Drug Saf* **29:** 49-66.

Stuart JM, Watson WC and Kang AH (1988). Collagen autoimmunity and arthritis. *FASEB J* **2:** 2950-2956.

Tak PP and Kalden JR (2011) Advances in rheumatology: new targeted therapeutics. *Arthritis Res Ther* **13 Suppl 1:** S5.

Xu Z, Dziarski R, Wang Q, Swartz K, Sakamoto KM and Gupta D (2001) Bacterial peptidoglycan-induced tnf-alpha transcription is mediated though the transcription factors Egr-1, Elk-1, and NF-kappaB. *J Immunol* **167:** 6975-6982.

Yao J, Mackman N, Edgington TS and Fan ST (1997) Lipopolysaccharide induction of the tumor necrosis factor-alpha promoter in human monocytic cells. Regulation by Egr-1, c-Jun, and NF-kappaB transcription factors. *J Biol Chem* **272:** 17795-17801.

Yoon SI, Kurnasov O, Natarajan V, Hong M, Gudkov AV, Osterman AL and Wilson IA (2012) Structural basis of TLR5-flagellin recognition and signaling. *Science* **335:** 859-864.

Zalevsky J, Secher T, Ezhevsky SA, Janot L, Steed PM, O'Brien C, Eivazi A, Kung J, Nguyen DH, Doberstein SK, Erard F, Ryffel B and Szymkowski DE (2007) Dominant-negative inhibitors of soluble TNF attenuate experimental arthritis without suppressing innate immunity to infection. *J Immunol* **179:** 1872-1883.

Figure Legends

Figure 1. Effect of AN3485 on human PBMCs and monocytes viability. Human PBMCs (A) and monocytes (B) were stimulated with LPS in the presence of AN3485 for indicated time periods. The cell viability was determined by further incubation of the cells with MTS solution as described in Materials and Methods.

Figure 2. AN3485 inhibits LPS-induced cytokines at mRNA and protein levels. Freshly isolated human monocytes from individual donor's buffy coat were stimulated with LPS in the presence of AN3485 for indicated time periods. The mRNA of a cytokine was quantitated by qPCR and normalized to the level of GAPDH (A), and cytokines in the culture supernatant were determined (B). Each value represents the mean $\pm$ SD of triplicates. Statistical significance compared to untreated control (*, $p<0.05$; **, $p<0.005$; ***, $p<0.001$).

Figure 3. AN3485 inhibits Zymosan-, Poly I:C- and Flagellin-induced cytokines at mRNA and protein levels. Freshly isolated human monocytes were stimulated with Zymosan, Poly I:C or Flagellin in the presence of AN3485 for indicated time periods. The mRNA of a cytokine was quantitated by qPCR and normalized to the level of GAPDH (A), and cytokines in the culture supernatant were determined (B). Each value represents the mean $\pm$ SD of triplicates. Statistical significance compared to untreated control (*, $p<0.05$; **, $p<0.005$; ***, $p<0.001$).

Figure 4. Oral administration of AN3485 inhibits LPS-induced TNF-α and IL-6 in mice. AN3485 in plasma after 2 h of administration is indicated in blue. Each value represents the mean $\pm$ SD of 10 mice each group.

Figure 5.   Seven day toxicity study of oral AN3485. Mice were either untreated, or orally administrated once a day with 100 mg/kg of AN3485 or vehicle for 7 days. Body weights were recorded (A), hematology of blood collected on day 8 was assessed (B), and spleen weights, percentage of $CD3^+$, $B220^+$ and $CD11b^+$ cells in spleens on day 8 were analyzed (C). The data represent the mean $\pm$ SD of 5 mice each group. Statistical significance compared to vehicle group (*, $p<0.05$; **, $p<0.005$).

Figure 6.   Topical application of AN3485 reduces PMA-induced contact dermatitis. Mice ear edema (A) and cytokines in ears (B) were determined 6 h after PMA stimulation. Each value represents the mean $\pm$ SD of 5 mice each group. Dex, dexamethasone. Statistical significance compared to vehicle group (*, $p<0.05$; **, $p<0.005$; ***, $p<0.001$).

Figure 7.   Topical AN3485 suppresses oxazolone-induced delayed-type hypersensitivity. Mice ear swelling (A) and cytokines in ears (B) were determined 24 h after oxazolone challenge. Each value represents the mean $\pm$ SD of 5 mice each group. Dex, dexamethasone. Statistical significance compared to vehicle group (*, $p<0.05$; **, $p<0.005$; ***, $p<0.001$).

Figure 8. Oral administration of AN3485 attenuates collagen-induced arthritis in mice. Disease development (cumulative disease score) was assessed three times a week (A), histological evaluation of joints was performed on day 20 after drug regimen with toluidine blue staining (B), and histological scores of synovial inflammation, pannus, cartilage damage and bone resorption were quantitated, and statistical significant from vehicle group ($p <0.001$ for all of these

parameters) (C). W indicates wrist, and the arrows indicate some of the affected joints with

significant cartilage and bone erosion and tissue swelling (magnification 16x).

Tables

Table 1. Inhibition of LPS-induced TNF-α, IL-1β and IL-6 secretion from PBMCs and isolated

monocytes. Human PBMCs or monocytes were stimulated with 1 μg/ml of LPS for 24 h in the

presence of serial 10-fold diluted AN3485 with final concentration ranging from 0.1 nM - 100

μM. Cytokines in the culture supernatants were analyzed by using Cisbio HTFR cytokine

determination kits. The data are the average of at least 4 independent experiments, mean $\pm$ SD.

AN3485	IC$_{50}$ TNF-α (nM)	IC$_{50}$ IL-1β (nM)	IC$_{50}$ IL-6 (nM)
PBMCs	103 $\pm$ 68	68 $\pm$ 63	72 $\pm$ 33
Monocytes	77 $\pm$ 26	18 $\pm$ 6.7	32 $\pm$ 6.5

Table 2. AN3485 inhibits Zymosan- and Poly I:C-induced cytokine production. Human PBMCs

were stimulated with Zymosan and Poly I:C for 24 h in the presence of 10-fold serial dilution of

AN3485 with final concentration ranging from 0.1 nM – 100 µM. Cytokines in the culture

supernatants were quantitated by using Cisbio HTRF cytokine determination kits. The data are

average of 3 or more independent experiments, mean ± SD.

	Zymosan	Poly I:C
IC_{50} TNF-α (nM)	580 ± 270	220 ± 290
IC_{50} IL-1β (nM)	350 ± 370	28 ± 33
IC_{50} IL-6 (nM)	170 ± 62	72 ± 50

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

A.

B.

	WBC (x10^3/μl)	RBC (x10^6/μl)	Reticulocytes (x10^9/l)	platelets (x10^3/μl)	neutrophils (x10^3/μl)	lymphocytes (x10^3/μl)	HGB (g/dl)	HCT (%)	MCV (fL)
untreated	2.17 ± 0.73	9.08 ± 0.71	328.04 ± 158.71	1141 ± 187.84	0.14 ± 0.18	1.19 ± 0.73	14.52 ± 1.32	46.88 ± 4.67	51.58 ± 1.41
vehicle	3.16 ± 0.79	9.58 ± 0.55	236.88 ± 74.41	1207 ± 231.01	0.078 ± 0.03	1.53 ± 0.45	15.33 ± 0.64	48.18 ± 2.29	50.35 ± 1.42
AN3485 100mg/kg	2.1 ± 0.42*	9.44 ± 1.18	184.64 ± 72.85	819.2 ± 223.17*	0.16 ± 0.27	1.05 ± 0.42*	13.94 ± 0.38**	44.58 ± 0.46*	47.82 ± 5.78

C.

Figure 6

A.

Ear Edema

Dex (mg/ear)	-	0.3	-	0.3	1
AN3485 (mg/ear)	-	-	0.1	0.3	1
p value		**		***	***

B.

IL-6

Dex (mg/ear)	-	0.3	-	-	-
AN3485 (mg/ear)	-	-	0.1	0.3	1
p value		**	*	***	***

IL-1β

Dex (mg/ear)	-	0.3	-	-	-
AN3485 (mg/ear)	-	-	0.1	0.3	1
p value			*	**	***

Figure 7

A.

Ear Edema

Dex (mg/ear)	-	0.3	-	0.3	1
AN3485 (mg/ear)	-	-	0.1	0.3	1
p value		***	*	***	***

B.

IL-1β

Dex (mg/ear)	-	0.3	-	0.3	1
AN3485 (mg/ear)	-	-	0.1	0.3	1
p value		***		*	**

IL-6

Dex (mg/ear)	-	0.3	-	0.3	1
AN3485 (mg/ear)	-	-	0.1	0.3	1
p value		***		*	***

TNF-α

Dex (mg/ear)	-	0.3	-	0.3	1
AN3485 (mg/ear)	-	-	0.1	0.3	1
p value		***		*	***

IL-4

Dex (mg/ear)	-	0.3	-	0.3	1
AN3485 (mg/ear)	-	-	0.1	0.3	1
p value		***		*	***

Figure 8